Trends in cancer-targeted antibody-drug conjugates.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 1, doi. 10.1007/s11523-013-0302-9
- By:
- Publication type:
- Article
Works matching IS 17762596 AND DT 2014 AND VI 9 AND IP 1
Results: 9
1
2
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 43, doi. 10.1007/s11523-013-0260-2
- By:
- Publication type:
- Article
3
Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 63, doi. 10.1007/s11523-013-0276-7
- By:
- Publication type:
- Article
4
Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 9, doi. 10.1007/s11523-013-0304-7
- By:
- Publication type:
- Article
5
Caffeic acid phenylethyl ester and MG132, two novel nonconventional chemotherapeutic agents, induce apoptosis of human leukemic cells by disrupting mitochondrial function.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 25, doi. 10.1007/s11523-013-0256-y
- By:
- Publication type:
- Article
6
Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 85, doi. 10.1007/s11523-014-0313-1
- By:
- Publication type:
- Article
7
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 81, doi. 10.1007/s11523-012-0245-6
- By:
- Publication type:
- Article
8
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 73, doi. 10.1007/s11523-013-0267-8
- By:
- Publication type:
- Article
9
Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 1, p. 53, doi. 10.1007/s11523-013-0269-6
- By:
- Publication type:
- Article